Dravet 症候群市場規模、佔有率和成長分析：按診斷、治療/管理、類型和地區 - 產業預測，2024-2031 年

2022 年 Dravet 症候群市場規模為 3.4385 億美元，從 2023 年的 3.7617 億美元擴大到 2031 年的 7.7184 億美元，預計在預測期內（2024-2031 年）將以 9.4% 的複合年成長率。

Dravet 症候群，也稱為嬰幼兒嚴重肌陣攣性癲癇 (SMEI)，其特徵是反覆癲癇發作，通常由發燒或體溫升高引發。這種罕見的神經系統疾病通常會持續一生，並從幼兒期開始影響人們。它通常在生命的第一年內發生，最初見於健康嬰兒。隨著疾病的進展，發作變得更加頻繁，其治療充滿挑戰和併發症。 Dravet 症候群的獨特特徵強調了專業醫療照護和對患者及其家人持續支持的至關重要性。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 價格分析
• 價值鏈分析
• 市場生態系統
• Start-Ups分析
• 監管環境
• 創新矩陣
• 主要投資分析
• 關鍵成功因素
• 市場魅力指數
• 競爭程度

Dravet 症候群市場：按診斷

• 市場概況
• 核磁共振檢查
• 腦電圖測試
• SCN1A測試

Dravet 症候群市場：依治療與管理分類

• 市場概況
• 癲癇藥物
• 生酮飲食
• 迷走神經刺激

Dravet 症候群市場：依類型

• 市場概況
• 製藥公司
• 醫院
• 診斷實驗室
• 學術/研究機構
• 其他

Dravet 症候群市場：依癲癇類型

• 市場概況
• 肌陣攣發作
• 失張力發作
• 局部性發作
• 失神發作
• 強直陣攣發作
• 光敏性癲癇發作

Dravet 症候群市場規模：依地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• GW Pharmaceuticals plc（United Kingdom）
• Zogenix, Inc.（United States）
• Ovid Therapeutics Inc.（United States）
• Biocodex SA（France）
• Takeda Pharmaceutical Company Limited（Japan）
• PTC Therapeutics, Inc.（United States）
• Epygenix Therapeutics, Inc.（United States）
• Stoke Therapeutics, Inc.（United States）
• UCB SA（Belgium）
• Biscayne Neurotherapeutics, Inc.（United States）
• Anavex Life Sciences Corp.（United States）
• Marinus Pharmaceuticals, Inc.（United States）
• Neurocrine Biosciences, Inc.（United States）
• INSYS Therapeutics, Inc.（United States）
• Otsuka Holdings Co., Ltd.（Japan）
• Aquestive Therapeutics, Inc.（United States）
• Epygenix Therapeutics（United States）
• Eisai Co., Ltd.（Japan）
• Zogenix International Limited（Ireland）
• Tevard Biosciences GmbH（Germany）

Dravet Syndrome Market size was valued at USD 343.85 million in 2022 and is poised to grow from USD 376.17 million in 2023 to USD 771.84 million by 2031, growing at a CAGR of 9.4% in the forecast period (2024-2031).

Dravet syndrome, also called severe myoclonic epilepsy of infancy (SMEI), commonly manifests with recurring seizures often induced by fever or elevated body temperature. This rare neurological condition typically persists throughout life, impacting individuals from early childhood onward. It typically starts within the first year of life and is initially identified in otherwise healthy infants. As the syndrome progresses, seizures become more frequent, posing challenges and complications in its management. The distinct characteristics of Dravet syndrome emphasize the critical need for specialized medical attention and continuous support for both affected individuals and their families.

Top-down and bottom-up approaches were used to estimate and validate the size of the Dravet Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Dravet Syndrome Market Segmental Analysis

The global Dravet Syndrome market is segmented based on diagnosis, treatment & management, type of seizures, end user, and region. Based on diagnosis, the market is segmented into MRI, EEG, SCN1A testing, and others. Based on treatment & management, the market is segmented into Seizure medications, A ketogenic diet, Vagus nerve stimulation, and Others. Based on type of seizures, the market is segmented into Myoclonic Seizures, Atonic Seizures, Absence Seizures, Photosensitive Seizures, Partial Seizures, and Others. Based on end user, the market is segmented into Pharmaceutical companies, hospitals, diagnostic laboratories, academic & research institutes, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific Latin America, and Middle East & Africa.

Drivers of the Dravet Syndrome Market

Genetic mutations, particularly those involving the SCN1A gene, are a major factor in triggering Dravet syndrome in children, with around 80-90% of cases linked to mutations in this specific gene. Advances in genetic testing technology are anticipated to boost market revenue for testing methods. Sophisticated diagnostic approaches such as dual detection, deletion analysis, and mosaicism testing are crucial for accurately and efficiently diagnosing genetic abnormalities associated with Dravet syndrome. These advancements promise to enhance diagnostic precision and contribute to improved patient care outcomes.

Restraints in the Dravet Syndrome Market

The projected revenue growth for Dravet Syndrome could encounter challenges due to several factors. Epilepsy and related seizure disorders have historically been surrounded by societal stigma, discrimination, misinformation, and fear on a global scale. This pervasive stigma linked with the condition may discourage individuals from seeking treatment, as they may fear the consequences of being associated with such a diagnosis. This could potentially hinder efforts to effectively address and manage the condition.

Market Trends of the Dravet Syndrome Market

Recent advancements in regulatory approvals have significantly propelled efforts in managing Dravet Syndrome. Particularly, the approval of medications like stiripentol (Diacomit) and Epidiolex has proven instrumental in treating symptoms associated with the disorder. These regulatory milestones represent significant progress in addressing the severe complexities of Dravet syndrome. Additionally, anticipation of forthcoming regulatory approvals, such as Zogenix's submission of a New Drug Application (NDA) for its clinical candidate ZX008 (Fintepla), is poised to further accelerate market growth.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Start-up Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Market Attractive Index
• Degree of Competition

Global Dravet Syndrome Market by Diagnosis

• Market Overview
• MRI Testing
• EEG Testing
• SCN1A Testing

Global Dravet Syndrome Market by Treatment & Management

• Market Overview
• Seizure medications
• A ketogenic diet
• Vagus nerve stimulation

Global Dravet Syndrome Market by Type

• Market Overview
• Pharmaceutical Companies
• Hospitals
• Diagnostic Laboratories
• Academic & research institutes
• Others

Global Dravet Syndrome Market by Type of Seizures

• Market Overview
• Myoclonic Seizures
• Atonic Seizures
• Partial Seizures
• Absence Seizures
• Tonic Clonic Seizures
• Photosensitive Seizures

Global Dravet Syndrome Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• GW Pharmaceuticals plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zogenix, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ovid Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocodex S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epygenix Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stoke Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biscayne Neurotherapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anavex Life Sciences Corp. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Marinus Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• INSYS Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aquestive Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epygenix Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zogenix International Limited (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tevard Biosciences GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments